Tours and activities, as a subset of the travel industry, have quickly grown from a niche category to become one of the most rapidly growing sources of revenue.
Tours and activities, as a subset of the travel industry, have quickly grown from a niche category to become one of the most rapidly growing sources of revenue.
Welcome to Part 2 of our exploration into the most promising small-cap stocks to watch in 2025. In Part 1, we uncovered a diverse range of companies making strides in
As we grapple with the increasing demands of a growing population and the pressing need for sustainable practices, a revolutionary industry is rising to meet the challenge head-on: cellular agriculture.
Visa has announced a $100 million investment in enterprises creating generative AI technology and applications that could influence the future of commerce and payments.
Sondrel (Holdings) plc, the fabless semiconductor business providing turnkey services in the design and delivery of ‘application specific integrated circuits’ (“ASICs”) and ‘system on chips’ (“SoCs”) for leading global technology
AstraZeneca has decided to abandon the pledge of not-for profit made during the pandemic and aims to make a modest profit from COVID-19 vaccinations.
Every drug has its beneficiaries, whether they are suffering from a common chronic disease, a more severe form of cancer or a rare condition that affects 1 in 10,000 people. However,
DeepMatter Group PLC today announced it has signed a contract to trial its DigitalGlassware® platform with Aurigene Pharmaceutical Services based in Hyderabad, India, to supply its DigitalGlassware® platform.
Roche has selected PathAI to collaborate with it on an artificial intelligence program that will be merged with its digital pathology work.
Automated chemistry has been a priority for many companies since the outbreak of the pandemic. Paul Whittles is the sales director at Deepmatter Group (a company based in Glasgow, UK
Science in Wales is booming, photonics company Sulis Technology and Imperial College London passed phase 1 human trials for a cancer detection system where a flurofore is added to the body